

Hepatology COVID-19 Registry Week 12 Report

2 new cases added to the report since last week


	Liver disease, Non-Transplant (N=23)	Post-liver transplantation (N=22)
Gender (%)	Female = 10 (43.47%)	Female = 10 (45.45 %)
	Male = 13 (56.53%)	Male = 12 (54.54 %)
Median Age (yr) at time of COVID diagnosis (range)	5 (0.16-20)	13.5 (0.5-21)
Etiology of liver disease	Biliary atresia = 7	Biliary atresia = 8
	NAFLD = 5	Acute liver failure = 6
	Autoimmune hepatitis = 5	Metabolic disorders = 2
	Metabolic disorder = 1	Tumor = 2
	Acute Liver Failure = 1	Others** = 4
	Others* = 4	
Highest level of care		
Outpatient	7	16
Hospital floor	9	3
ICU	7	3
Immunosuppression at time	No Immunosuppression = 18	Tacrolimus = 18
of COVID diagnosis	Azathioprine = 5	Steroids = 9
(*some patients were on multiple	Steroids =3	Mycophenolate Mofetil = 8
agents)		Sirolimus = 3
		Azathioprine = 1
		Cyclosporine =1
Specific Treatment for COVID	Hydroxychloroquine + Azithromycin = 3	Hydroxychloroquine = 2
(*some patients were on multiple	IVIG = 4	Azithromycin = 1
agents)	Steroids = 3	IVIG = 1
	Remdesivir = 2	Favipiravir = 1
	Tocilizumab + Sarilumab = 1	
	Rocilizumab Sarilumab = 1	
	Convalescent Plasma = 1	
	Anakinra = 1	
	Eculizimab = 1	
Highest respiratory support		
None	16	18
Nasal cannula/CPAP/BiPAP	3	2
Mechanical ventilation	3	0
High Frequency Oscillatory ventilation	1	0
Pending information	-	2
Final clinical outcome		
Death	1***	0
Recovery	20	17
Still active in clinical course	2	2
Pending information	-	3
Liver related Complications	Ascites = 6	-
	Portal Hypertension Bleeding =1	
	Infection = 1	

*Others CLD: idiopathic cholestasis, GVHD/vanishing bile duct syndrome (Post BMT), IFALD with biliary obstruction, PFIC

** Others PLT: IFALD , Congenital hepatic fibrosis, AIH-Sclerosing cholangits


***Pulmonary hemorrhage, multi-organ failure

Presenting symptoms at time of diagnosis



^{*}Constitutional symptoms reported: Loss of smell/taste , fever, myalgia, fatigue, sore throat # Other symptoms reported: Malaise, anorexia, headache, rash, Kawasaki disease like presentation(MIS-C)

Change done to Immunosuppressive agent (Post LT)



*Stopped, decreased the dose, others and No changes Commonest agent **stopped**: Mycophenolate Mofetil